12:07 IST
BSE
Other Announcement
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals Ltd submitted its shareholding pattern for the quarter ended 31 March 2026, in compliance with SEBI regulation 31(1)(b).
Senores Pharmaceuticals Ltd
- Share price
- ₹1,391.10
- Market cap
- ₹6,407 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 50.7×Sector 47.4×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 5Earnings Call 5Financial Results 4Annual General Meeting 4Management Change 3Results Update 2Fund Raise 2Debt & Borrowing 2Board Meeting Date 2Results Correction 1Promoter Selling (Off-Market) 1Promoter Buying (Off-Market) 1Price Movement Clarification 1Merger & Restructuring 1Business Update 1Annual Report 1
Time
5 announcements with these filters
14:40 IST
BSE
Other Announcement
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals Ltd filed its quarterly shareholding pattern as mandated by SEBI regulations for the period ended June 30, 2026.
12:12 IST
BSE
Other Announcement
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals Ltd filed its quarterly shareholding pattern. The document details equity holdings across promoters, institutions, and public shareholders.
17:19 IST
BSE
Other Announcement
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals Limited submitted its Annual Secretarial Compliance Report for FY 2025-26. The auditor confirmed general compliance with SEBI regulations and secretarial standards.
17:19 IST
NSE
Other Announcement
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals Limited submitted its Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026. The report confirms a total issued capital of 4,60,53,588 shares, with 100% held in dematerialized form. It also notes a preferential allotment of 11,70,000 convertible equity warrants on March 28, 2026.